Botulinum toxin type A was the top non-surgical cosmetic procedure of 2010, according to recent stats from the American Society of Plastic Surgeons (ASPS). While Botox and Dysport have proved their popularity as injectable wrinkle fillers, the companies that make them continue to look for new uses.
A CBS Interactive Business Network report gives an update on what the future may hold for these products. For instance, Medicis, maker of Dysport, is working with a company called Revance to create a wipe-on, wipe-off version of botulinum toxin to treat facial wrinkles and excessive sweating.
Meanwhile Allergan, maker of Botox, is currently researching the drug for use as a painkiller and as a treatment for juvenile cerebral palsy and enlarged prostate.
Allergan also continues to focus on Botox’s huge success as a wrinkle filler with a new website that allows users to upload their own photos and then create photos of what they might look like after Botox.
Botox was also recently approved as a preventive treatment for chronic migraine in October 2010.
The CBS report says sales of Allergan’s Botox began recovering last year after declining during the recession, and ASPS statistics show that cosmetic minimally-invasive procedures increased 5 percent in 2010 from 2009.
Dysport, which was released by Medicis in 2009, has also seen sales success. The company’s non-acne skin products were up 31 percent in 2010, and most of that increase was probably due to Dysport.
Learn more about current specials on Botox and Dysport from About Face Cosmetic Surgery.